



Equivir/Nemovir



TECHNOLOGY DESCRIPTION

Equivir/Nemovir technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols (e.g. Myricetin, Hesperetin, Piperine) which have demonstrated antiviral effects with additional potential application as health supplements or medication. Polyphenols are sourced from fruits, vegetables, and other natural substances.

Myricetin is a member of the flavonoid class of polyphenolic compounds with antioxidant properties. Hesperetin is a flavanone and Piperine is an alkaloid, commonly found in black pepper.

PATENTS/INTELLECTUAL PROPERTY SUMMARY

Thompson, Daryl Lee. 2019. Method and composition for preventing and treating viral infections. U.S. Patent #10,383,842 issued August 20, 2019. Patent was filed under the Patent Cooperation Treaty (PCT).

The method includes administering a composition that includes therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, and an ICAM-1 inhibitor to a patient at risk of, or diagnosed with, a viral infection which each down regulate the immune cytokine response.

MARKET OVERVIEW (SIZE, COMPETITION, TRENDS)

The global health supplement market is growing at 8% CAGR and is projected to reach \$70B in 2024.

Source: *Persistence Market Research*

Market size and growth rate will vary by specific indication.

VALUE PROPOSITION/BASIS FOR DIFFERENTIATION

Worldwide efficacy of vaccines varies by virus type.

Equivir/Nemovir has demonstrated in vitro efficacy against multiple viruses including several strains of influenza, rhinovirus, Ebola, and COVID-19.

Continued

Continued

PRODUCT DEVELOPMENT STATUS

Compound development, safety, and stability are complete.

FINANCIALS

Time-to-market and time-to-revenue are contingent on target claims and legal and regulatory requirements.

POTENTIAL AGREEMENT STRUCTURE(S)

Equivir/Nemovir is available for worldwide licensing, joint venture, and/or co-development agreements.

COMPANY SUMMARY AND CONTACT INFORMATION

Impact BioMedical, Inc. is a wholly-owned subsidiary of Document Security Systems, Inc. and drives mission-oriented research and development that addresses unmet needs in human healthcare.

Impact BioMedical, Inc. has worldwide rights to Equivir/Nemovir technology and is seeking partners to develop and/or commercialize this technology.

For more information:

<https://www.impbio.com>

<https://www.dsssecure.com>

Contact:

Mark Suseck

Chief Business Officer

Impact BioMedical, Inc.

+1 908 310 2613

MSuseck@impactbiomedinc.com